Navigation Links
Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy
Date:5/4/2010

> (Intl. J. Oncology, April, 2010) highlights important aspects of Rexin-G bio-pharmacology, as this tumor-targeted vector advances as an efficacious anti-cancer agent. What the reader will gain: These remarkable case studies, in and of themselves, reveal important aspects of the molecular pharmacology, advanced clinical protocols, refinement of patient monitoring, expanding treatment options, and strategic medical approaches to patient care that exemplify and thereby extend the established principles of pathotropic targeting and cancer gene therapy to a new generation of clinical practitioners. Take home message:  Each case study, in an otherwise intractable cancer, "teaches" a vital lesson in the emerging praxis of cancer control.

Finally, the third article comes in the form of a Minireview entitled "Nanoparticles and the Immune System" (Endocrinology, Feb, 2010) co-authored by members of the FDA Center for Drug Evaluation and Research, Office of Pharmaceutical Science, and the Nanotechnology Characterization Laboratory of the National Cancer Institute. What the reader will gain: This astute review of medical nanotechnology aptly describes the concept of targeted delivery of Rexin-G followed by Reximmune-C as a two-tier complementary approach aimed at both tumor eradication and personalized cancer vaccination. That is, the first step involves the use of Rexin-G to target and control the progression of metastatic cancer, whereas the second step employs Reximmune-C to induce a localized cancer immunization. Take home message: This is a commendable and timely review of these first-in-class,
'/>"/>

SOURCE Epeius Biotechnologies Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Epeius Biotechnologies Corporation Expands its Rexin-G Production Facilities in Southern California
2. Epeius Biotechnologies to Partner at BIO Investor Forum
3. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
4. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
5. Targeting Metastatic Cancer From the Inside: Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery
6. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
7. FDA Grants Epeius Biotechnologies Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
8. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
9. Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
10. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
11. Glycos Biotechnologies Expands Management Team with Appointment of Vice President of Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 Demanding industrial and ... engineered of synthetic Sapphire and Glass Ball Lenses, now ... Swiss Jewel Company , of Philadelphia , PA. ... and collimating the light beams without the need for ... and natural durability (9 mohs) make it the ideal ...
(Date:6/18/2013)... 18, 2013 RegeneCure announced ...  proprietary AMCA Guided Bone Regeneration (GBR) Dental Membrane as a ... A common problem encountered when patients have a tooth replaced ... volume to house the implant. Consequently there is often a ... the natural bone regenerates. The bone substitute material, in turn, ...
(Date:6/18/2013)... , June 18, 2013  AMRI (NASDAQ: ... Burlington, Mass. , site has ... Enforcement Administration (DEA) registration to handle Schedule 2 ... DEA,s acknowledgement of Burlington,s ... and documentation. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) ...
(Date:6/18/2013)... June 18, 2013 This webinar ... pharmaceutical advertising and promotion, and review the basic ... learn how to apply these principles through real ... ,     The fundamentals on FDA regulations and ... labeling ,     Assessing traditional and newer forms ...
Breaking Biology Technology:Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2
... Novocell, Inc. , a preclinical stage diabetes ... award totaling $20 million from the California Institute for Regenerative ... scientists at the University of California, San Francisco (UCSF), led ... million. The funding will advance Novocell,s development of a first ...
... Nev., Oct. 28 PDL BioPharma, Inc. (PDL) (Nasdaq: ... a $300 million securitization transaction intended to monetize certain ... closing of the transaction, which is expected to occur ... QHP Royalty Sub LLC ("QHP"), a newly-formed wholly-owned subsidiary ...
... Novavax, Inc. (Nasdaq: NVAX ) announced ... joint venture between Cadila Pharmaceuticals in India, has ... will be used to produce pandemic and seasonal ... virus-like particle (VLP) vaccine technology to produce commercial-scale ...
Cached Biology Technology:Novocell Receives a Disease Team Award for $20 Million from the California Institute for Regenerative Medicine to Develop a Stem Cell Therapy for the Treatment of Diabetes 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 3Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 2Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 3Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 4Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 5
(Date:6/18/2013)... expecting a very large "dead zone" in the Gulf ... in the Chesapeake Bay this year, based on several ... of Michigan, Louisiana State University, and the Louisiana ... of Mexico hypoxic "dead" zone will be between 7,286 ... the ten largest recorded. That would range from an ...
(Date:6/18/2013)... awarded $12.7 million to match nine academic research ... to explore new treatments for patients in eight ... and schizophrenia. The collaborative pilot initiative, called Discovering ... by the National Center for Advancing Translational Sciences ... , The process of developing a new therapeutic ...
(Date:6/18/2013)... Bethesda, MD, June 18, 2013: The Association for Molecular ... Federation of American Societies for Experimental Biology (FASEB) on ... for membership on June 3, 2013. , The ... individuals and share a common vision for the advancement ... "Basic biomedical and translational research is more important now ...
Breaking Biology News(10 mins):NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 3NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 4NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4
... sites of fundamental geodynamic, geochemical and biological processes and ... for us. Scientific marine drilling and coring is crucial ... (sub-) seafloors to advance our knowledge in the Earth ... (ESF) European Collaborative Research (EUROCORES) programme EuroMARC is an ...
... Calif., November 23, 2008 -- Peregrine Pharmaceuticals, Inc. ... Nature Medicine that supports the broad ... antibody platform, showing that its PS-targeting drug bavituximab ... models. Bavituximab is in clinical ...
... Futronic Technology Company Limited, a,global provider of ... of FS22, a high performance fingerprint access and,attendance ... launched,FS21M (mid-range device) and FS20 (low cost device), ... and attendance control device.,FS22 uses a powerful Digital ...
Cached Biology News:Europe cores in EUROCORES: Ocean drilling in EuroMARC 2Europe cores in EUROCORES: Ocean drilling in EuroMARC 3Europe cores in EUROCORES: Ocean drilling in EuroMARC 4Europe cores in EUROCORES: Ocean drilling in EuroMARC 5Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections 2Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections 3Futronic Launches FS22 Fingerprint Access Control Device 2
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
Request Info...
... Nuclease catalyzes the degradation of single-stranded DNA ... products. While the nuclease prefers ssDNA over ... the enzyme degrades double-stranded DNA from both ... used for transcript mapping studies (3,4), for ...
Biology Products: